IL247290B - שיטות לטיפול או מניעה של אסטמה על ידי הוספה של אנטגוניסט של il–4r - Google Patents

שיטות לטיפול או מניעה של אסטמה על ידי הוספה של אנטגוניסט של il–4r

Info

Publication number
IL247290B
IL247290B IL247290A IL24729016A IL247290B IL 247290 B IL247290 B IL 247290B IL 247290 A IL247290 A IL 247290A IL 24729016 A IL24729016 A IL 24729016A IL 247290 B IL247290 B IL 247290B
Authority
IL
Israel
Prior art keywords
antagonist
treating
administering
maintenance doses
methods
Prior art date
Application number
IL247290A
Other languages
English (en)
Other versions
IL247290A0 (he
Original Assignee
Sanofi Biotechnology
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2015/016852 external-priority patent/WO2015127229A1/en
Application filed by Sanofi Biotechnology, Regeneron Pharma filed Critical Sanofi Biotechnology
Publication of IL247290A0 publication Critical patent/IL247290A0/he
Publication of IL247290B publication Critical patent/IL247290B/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
IL247290A 2014-02-21 2016-08-16 שיטות לטיפול או מניעה של אסטמה על ידי הוספה של אנטגוניסט של il–4r IL247290B (he)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461943019P 2014-02-21 2014-02-21
EP14306413 2014-09-15
US201462077669P 2014-11-10 2014-11-10
PCT/US2015/016852 WO2015127229A1 (en) 2014-02-21 2015-02-20 Methods for treating or preventing asthma by administering an il-4r antagonist

Publications (2)

Publication Number Publication Date
IL247290A0 IL247290A0 (he) 2016-09-29
IL247290B true IL247290B (he) 2021-06-30

Family

ID=66624883

Family Applications (2)

Application Number Title Priority Date Filing Date
IL247290A IL247290B (he) 2014-02-21 2016-08-16 שיטות לטיפול או מניעה של אסטמה על ידי הוספה של אנטגוניסט של il–4r
IL283422A IL283422A (he) 2014-02-21 2021-05-25 שיטות לטיפול או מניעה של אסטמה על ידי הוספה של אנטגוניסט של il-4r

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL283422A IL283422A (he) 2014-02-21 2021-05-25 שיטות לטיפול או מניעה של אסטמה על ידי הוספה של אנטגוניסט של il-4r

Country Status (2)

Country Link
JP (2) JP6893265B2 (he)
IL (2) IL247290B (he)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
JP2014533246A (ja) * 2011-11-01 2014-12-11 メディミューン，エルエルシー 喘息の急性増悪の頻度および重症度を低下させる方法
IL312711A (he) * 2012-08-21 2024-07-01 Regeneron Pharma שיטות לטיפול או מניעה של אסטמה באמצעות מתן של אנאטגוניסט ל 4r–il

Also Published As

Publication number Publication date
JP7343547B2 (ja) 2023-09-12
IL283422A (he) 2021-06-30
JP6893265B2 (ja) 2021-06-23
IL247290A0 (he) 2016-09-29
JP2020105193A (ja) 2020-07-09
JP2021130695A (ja) 2021-09-09

Similar Documents

Publication Publication Date Title
MX2021004821A (es) Uso de antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia.
NZ748451A (en) Methods for treating atopic dermatitis by administering an il-4r antagonist
AU2018253544A1 (en) Methods for treating or preventing asthma by administering an IL-4R antagonist
EA033113B1 (ru) Способы лечения аутоиммунных, респираторных и воспалительных расстройств ингаляцией n-оксида рофлумиласта
MX2019006900A (es) Metodos de monitoreo terapeutico de farmacos depuradores de nitrogeno.
PH12014502048B1 (en) Treatment of cancer with tor kinase inhibitors
MX2017000366A (es) Terapia de combinacion para el cancer.
PH12014502046A1 (en) Treatment of cancer with tor kinase inhibitors
MX2016011333A (es) Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina.
PH12016502352A1 (en) Pharmaceutical composition
ZA202000028B (en) Use of vibegron to treat overactive bladder
BR112019002461A2 (pt) regime de dosagem para tratamento de tumores sólidos
MX2019001467A (es) Combinación de antagonistas del receptor de glucagon e inhibidores de la trayectoria p13k para el tratamiento del cáncer.
HK1243704A1 (zh) 用於在未接触疟疾的受试者中预防疟疾的他非诺喹的新方案
MX2018006779A (es) Terapia ciclica con 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-p iperidin-2,6-diona.
SG11202105551YA (en) Process for producing pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy
IL283422A (he) שיטות לטיפול או מניעה של אסטמה על ידי הוספה של אנטגוניסט של il-4r
TW201613600A (en) Piperazinyl derivative reduces HFD-induced accumulation of fat in the liver, therapeutically
PH12016502107A1 (en) Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
WO2020053664A8 (en) Combination therapy for the treatment of estrogen-receptor positive breast cancer
AR102494A1 (es) Métodos para tratar enfermedades oculares
UA94010U (uk) Спосіб лікування аденоміозу у жінок
Fabbrocini EMPACT syndrome: 2 case reports
UA111014C2 (uk) Спосіб лікування генералізованих тривожних розладів онкологічних хворих, які перенесли хірургічне втручання з формуванням кишкової стоми
UA84720U (ru) Способ лечения вегетативных дисфункций по гипотензивному типу у детей

Legal Events

Date Code Title Description
FF Patent granted